Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 143 No. 0708 (2013)

Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries

  • Jakob Passweg
  • Helen Baldomero
  • Mario Bargetzi
  • Christoph Bucher
  • Yves Chalandon
  • Michel A. Duchosal
  • Alois Gratwohl
  • Tayfun Güngör
  • Urs Hess
  • Kurt Leibundgut
  • Grazia Nicoloso de Faveri
  • Hulya Ozsahin
  • Thomas Pabst
  • Christoph Renner
  • Martin Stern
  • Georg Stussi
  • Urs Schanz
  • for the SBST (Swiss Blood Stem Cell Transplantation Group)
Cite this as:
Swiss Med Wkly. 2013;143:w13757


Haematopoietic stem cell transplantation (HSCT) is a highly specialised procedure used to treat malignancies of the lymphohaematopoietic system as well as some acquired and inherited disorders of the blood. This analysis by the Swiss Blood Stem Cell Transplantation Group, based on data from 2008–2011, describes, treatment rates in Switzerland for specific indications and compares this with data from Germany, France, Italy and the Netherlands, corrected for the size of the population. Differences in transplant rates, in rates for particular indications, and in the use of specific transplant technologies such as use of unrelated donors, use of cord blood or mismatched family donors are described. These data are put in correlation with donor availability from international registries and with number of transplant teams and number of procedures per team all corrected for population size.


  1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.
  2. Ljungman P, Bregni M, Brune M, Cornelissen J, deWitte T, Dini G, et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation. 2010;45:219–34.
  3. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285–99. Review.
  4. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–5.
  5. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007; 369(9577):1947–54.
  6. Gluckman E. Ten years of cord blood transplantation: from bench to bedside Br J Haematol. 2009;147(2):192–9.
  7. Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol. 2009;147(2):236–45.
  8. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28(17):2859–67.
  9. Gratwohl A, Schwendener A, Baldomero H, Gratwohl M, Apperley J Niederwieser D, et al. Changes in use of hematopoietic stem cell transplantation; a model for diffusion of medical technology. Haematologica. 2010;95:637–43.
  10. Blommestein HM, Verelst SG, Huijgens PC, Blijlevens NM, Cornelissen JJ, Uyl-de Groot CA. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol. 2012;91(12):1945–52.
  11. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10:209.
  12. Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. 2nd ed. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. d/b/a Outcome] under Contract No. HHSA290200500351 TO3.) AHRQ Publication No. 10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality. September 2010.
  13. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen Y-F. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment. 2010;54:1.141.
  14. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant. 2011;46(2):174–91.
  15. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A. Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in haematopoietic stem cell transplantation in Europe. Blood. 2002;100:2374–86.
  16. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012;47(7):906–23.
  17. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.
  18. Buhler S, Nunes JM, Nicoloso G, Tiercy JM, Sanchez-Mazas A. The Heterogeneous HLA Genetic Makeup of the Swiss Population. PLoS One. 2012;7(7):e41400. Epub 2012 Jul 25.
  19. Loberiza FR Jr, Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003;31(6):417–21.
  20. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2011;29(15):1980–6.
  21. Fausto R. Loberiza, Jr, Mei-Jie Zhang, Stephanie J. Lee, John P. Klein, Charles F. LeMaistre, Derek S. Serna, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States Blood. 2005;105:2979–87.

Most read articles by the same author(s)

1 2 3 > >>